Tanis: The going from one extreme to another in my
Post# of 30028
Posted On: 09/13/2014 2:13:40 PM
Tanis: The going from one extreme to another in my posts that you accuse me of is true. I agree with you on that.
During the last week of August I was very bullish. I thought we would be getting a "classic partner" on LymPro with 40 million up front. I thought that would juice the stock so that the revenue guidance go shareholders even more excited. I figured the pps would be somewhere in the .20 to .40 cent range by the end of September, not in the .10 cent range. (And from Gerald's discussion about it on the CC I don't think a Lympro JV is coming for quite some time!)
The emotion in my posts went from great exuberance to stunned, but cautious optimism after those announcements. Instead of believing the stock would up list in early December in the .40 cent and above range, I am struggling to find catalysts that will get us to .20 cents by then. I am also thinking up listing will be delayed until Q1 of 2015. MANF orphans will pop us up temporarily, but not for very long. MANF Partnerships are required for that.
So between the last week of August and the first week of September, the announcements Gerald made about LymPro were very different than I what I had expected. That is the reason for my change. It is not because I am trying to "soft bash" AMBS so I can do a "Solantey," as others here are trying to accuse me of.
With the Shareholder Meeting coming up and the billion share vote coming up, I felt this was the time to have this significant discussion.
I could be wrong.
During the last week of August I was very bullish. I thought we would be getting a "classic partner" on LymPro with 40 million up front. I thought that would juice the stock so that the revenue guidance go shareholders even more excited. I figured the pps would be somewhere in the .20 to .40 cent range by the end of September, not in the .10 cent range. (And from Gerald's discussion about it on the CC I don't think a Lympro JV is coming for quite some time!)
The emotion in my posts went from great exuberance to stunned, but cautious optimism after those announcements. Instead of believing the stock would up list in early December in the .40 cent and above range, I am struggling to find catalysts that will get us to .20 cents by then. I am also thinking up listing will be delayed until Q1 of 2015. MANF orphans will pop us up temporarily, but not for very long. MANF Partnerships are required for that.
So between the last week of August and the first week of September, the announcements Gerald made about LymPro were very different than I what I had expected. That is the reason for my change. It is not because I am trying to "soft bash" AMBS so I can do a "Solantey," as others here are trying to accuse me of.
With the Shareholder Meeting coming up and the billion share vote coming up, I felt this was the time to have this significant discussion.
I could be wrong.
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼